Found 3 hits in this display Target/Host
(Institution) | Ligand | Target/Host
Links | Ligand
Links | Trg + Lig
Links | Ki
nM | ΔG°
kJ/mole | IC50
nM | Kd
nM | EC50/IC50
nM | koff
s-1 | kon
M-1s-1 | pH | Temp
°C |
|---|
Lysophosphatidic acid receptor 1
(Homo sapiens (Human)) | BDBM251722
(US9464060, 58)Show SMILES COc1ccccc1O[C@H]1CC[C@@H](CC1)C(=O)N(CCCc1cccc(F)c1)Cc1ccc(cc1)C(O)=O |r,wU:12.16,wD:9.9,(-8.67,-5.39,;-7.34,-4.62,;-7.34,-3.08,;-8.67,-2.31,;-8.67,-.77,;-7.34,,;-6,-.77,;-6,-2.31,;-4.67,-3.08,;-3.33,-2.31,;-2,-3.08,;-.67,-2.31,;-.67,-.77,;-2,,;-3.33,-.77,;.67,,;.67,1.54,;2,-.77,;3.33,,;3.33,1.54,;4.67,2.31,;4.67,3.85,;3.33,4.62,;3.33,6.16,;4.67,6.93,;6,6.16,;7.34,6.93,;6,4.62,;2,-2.31,;3.33,-3.08,;3.33,-4.62,;4.67,-5.39,;6,-4.62,;6,-3.08,;4.67,-2.31,;7.34,-5.39,;7.34,-6.93,;8.67,-4.62,)| Show InChI InChI=1S/C31H34FNO5/c1-37-28-9-2-3-10-29(28)38-27-17-15-24(16-18-27)30(34)33(19-5-7-22-6-4-8-26(32)20-22)21-23-11-13-25(14-12-23)31(35)36/h2-4,6,8-14,20,24,27H,5,7,15-19,21H2,1H3,(H,35,36)/t24-,27- | PDB
UniProtKB/SwissProt
antibodypedia
GoogleScholar
AffyNet 
| PC cid
PC sid
UniChem
| US Patent
| n/a | n/a | 17 | n/a | n/a | n/a | n/a | n/a | 37 |
Takeda Pharmaceutical Company Limited
US Patent
| Assay Description
Engagement of the LPA1 receptor by its ligand, oleoyl-L-α-lysophosphatidic acid (LPA), leads to the release of intracellular stores of calcium into ... |
US Patent US9464060 (2016)
BindingDB Entry DOI: 10.7270/Q23R0RT0 |
More data for this
Ligand-Target Pair | |
Lysophosphatidic acid receptor 5
(Homo sapiens (Human)) | BDBM251722
(US9464060, 58)Show SMILES COc1ccccc1O[C@H]1CC[C@@H](CC1)C(=O)N(CCCc1cccc(F)c1)Cc1ccc(cc1)C(O)=O |r,wU:12.16,wD:9.9,(-8.67,-5.39,;-7.34,-4.62,;-7.34,-3.08,;-8.67,-2.31,;-8.67,-.77,;-7.34,,;-6,-.77,;-6,-2.31,;-4.67,-3.08,;-3.33,-2.31,;-2,-3.08,;-.67,-2.31,;-.67,-.77,;-2,,;-3.33,-.77,;.67,,;.67,1.54,;2,-.77,;3.33,,;3.33,1.54,;4.67,2.31,;4.67,3.85,;3.33,4.62,;3.33,6.16,;4.67,6.93,;6,6.16,;7.34,6.93,;6,4.62,;2,-2.31,;3.33,-3.08,;3.33,-4.62,;4.67,-5.39,;6,-4.62,;6,-3.08,;4.67,-2.31,;7.34,-5.39,;7.34,-6.93,;8.67,-4.62,)| Show InChI InChI=1S/C31H34FNO5/c1-37-28-9-2-3-10-29(28)38-27-17-15-24(16-18-27)30(34)33(19-5-7-22-6-4-8-26(32)20-22)21-23-11-13-25(14-12-23)31(35)36/h2-4,6,8-14,20,24,27H,5,7,15-19,21H2,1H3,(H,35,36)/t24-,27- | UniProtKB/SwissProt
antibodypedia
GoogleScholar
AffyNet
| PC cid
PC sid
UniChem
| US Patent
| n/a | n/a | 32 | n/a | n/a | n/a | n/a | n/a | 37 |
Takeda Pharmaceutical Company Limited
US Patent
| Assay Description
Engagement of the LPA5 receptor by its ligand, oleoyl-L-α-lysophosphatidic acid (LPA), leads to the release of intracellular stores of calcium into ... |
US Patent US9464060 (2016)
BindingDB Entry DOI: 10.7270/Q23R0RT0 |
More data for this
Ligand-Target Pair | |
Lysophosphatidic acid receptor 5
(Homo sapiens (Human)) | BDBM251721
(US9464060, 57)Show SMILES COc1ccccc1OC1CC[C@@H](CC1)C(=O)N(CCCc1cccc(F)c1)Cc1ccc(cc1)C(O)=O |r,wU:12.16,(-8.67,-5.39,;-7.34,-4.62,;-7.34,-3.08,;-8.67,-2.31,;-8.67,-.77,;-7.34,,;-6,-.77,;-6,-2.31,;-4.67,-3.08,;-3.33,-2.31,;-2,-3.08,;-.67,-2.31,;-.67,-.77,;-2,,;-3.33,-.77,;.67,,;.67,1.54,;2,-.77,;3.33,,;3.33,1.54,;4.67,2.31,;4.67,3.85,;3.33,4.62,;3.33,6.16,;4.67,6.93,;6,6.16,;7.34,6.93,;6,4.62,;2,-2.31,;3.33,-3.08,;3.33,-4.62,;4.67,-5.39,;6,-4.62,;6,-3.08,;4.67,-2.31,;7.34,-5.39,;7.34,-6.93,;8.67,-4.62,)| Show InChI InChI=1S/C31H34FNO5/c1-37-28-9-2-3-10-29(28)38-27-17-15-24(16-18-27)30(34)33(19-5-7-22-6-4-8-26(32)20-22)21-23-11-13-25(14-12-23)31(35)36/h2-4,6,8-14,20,24,27H,5,7,15-19,21H2,1H3,(H,35,36)/t24-,27? | UniProtKB/SwissProt
antibodypedia
GoogleScholar
AffyNet
| PC cid
PC sid
UniChem
| US Patent
| n/a | n/a | 410 | n/a | n/a | n/a | n/a | n/a | 37 |
Takeda Pharmaceutical Company Limited
US Patent
| Assay Description
Engagement of the LPA5 receptor by its ligand, oleoyl-L-α-lysophosphatidic acid (LPA), leads to the release of intracellular stores of calcium into ... |
US Patent US9464060 (2016)
BindingDB Entry DOI: 10.7270/Q23R0RT0 |
More data for this
Ligand-Target Pair | |